Menu
  • Join
  • Login
  • Contact
 

Search abstracts


The rheumatoid arthritis susceptibility polymorphism ptpn22 c1858t is not associated with leflunomide response or toxicity.

  • At: 2014 FIP Congress in PSWC, Melbourne (Australia)
  • Type: Poster
  • By: HOPKINS, Ashley Mark (University of South Australia, School of Pharmacy and Medical Sciences, Adelaide, Australia)
  • Co-author(s): O'Doherty (University of South Australia, Adelaide, Australia)
    Foster (University of South Australia, Adelaide, Australia)
    Suppiah (University of South Australia, Adelaide, Australia)
    Upton (University of South Australia, Adelaide, Australia)
    Spargo (Royal Adelaide Hospital, Adelaide, Australia)
    Cleland (Royal Adelaide Hospital, Adelaide, Australia)
    Proudman (Royal Adelaide Hospital, Adelaide, Australia)
    Wiese (University of South Australia, Adelaide, Australia)
  • Abstract:

    BackgroundA common polymorphism (C1858T) in the gene that encodes the protein tyrosine phosphatase non-receptor type 22 (PTPN22) is associated with altered T-cell responses and increased susceptibility to rheumatoid arthritis (RA) and other auto-immune diseases. Teriflunomide, the active metabolite of leflunomide, reduces T cell responses through..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses